Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN RUBINO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1962543280
CMS profile
43312
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,915.52

44 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,031.31 40
Travel and Lodging $884.21 4

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN RUBINO

NPI 1962543280 · CMS profile ID 43312

Allopathic & Osteopathic Physicians / Internal Medicine

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962543280?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962543280?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962543280?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1962543280?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

44 matching records · $1,915.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 44 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–44 of 44.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Endo USA, Inc. $18.8412/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138587140 CMS
Sumitomo Pharma America, Inc. $17.9112/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148912470 CMS
Merck Sharp & Dohme LLC $15.6911/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141624728 CMS
ABBVIE INC. $27.0311/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105985265 CMS
Medline Industries LP $32.8510/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144141025 CMS
Novartis Pharmaceuticals Corporation $17.3310/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158079 CMS
AstraZeneca Pharmaceuticals LP $16.1809/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104779228 CMS
ModernaTX, Inc. $35.8209/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152557885 CMS
ModernaTX, Inc. $288.9609/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152557893 CMS
ModernaTX, Inc. $240.0009/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152557909 CMS
ModernaTX, Inc. $89.7209/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152557921 CMS
ModernaTX, Inc. $265.5309/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152557937 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152557969 CMS
ModernaTX, Inc. $81.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152557971 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152557973 CMS
ModernaTX, Inc. $45.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152557975 CMS
ModernaTX, Inc. $120.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152557977 CMS
AstraZeneca Pharmaceuticals LP $15.5409/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104349444 CMS
Medtronic, Inc. $16.0209/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119569160 CMS
Novo Nordisk Inc $21.9008/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096661024 CMS
Astellas Pharma US Inc $14.4408/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139299100 CMS
Exact Sciences Corporation $15.8108/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114863516 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.3107/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118253050 CMS
Astellas Pharma US Inc $15.9507/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139273030 CMS
Exact Sciences Corporation $15.8907/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114863513 CMS
AstraZeneca Pharmaceuticals LP $34.7706/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104419115 CMS
Novo Nordisk Inc $27.0006/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097689781 CMS
E.R. Squibb & Sons, L.L.C. $17.5506/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101323334 CMS
Eisai Inc. $15.7905/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110754056 CMS
Abbott Laboratories $30.3705/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125360309 CMS
Otsuka America Pharmaceutical, Inc. $28.7705/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118973034 CMS
Novo Nordisk Inc $22.2305/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096698998 CMS
Medtronic, Inc. $22.5905/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119569158 CMS
AstraZeneca Pharmaceuticals LP $13.8104/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105480705 CMS
Novartis Pharmaceuticals Corporation $15.0304/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087158073 CMS
Amgen Inc. $14.3403/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117370369 CMS
Astellas Pharma US Inc $28.1903/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139324948 CMS
ABBVIE INC. $28.1903/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105985263 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21.0303/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153669638 CMS
Merck Sharp & Dohme LLC $16.3203/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141920286 CMS
Novo Nordisk Inc $16.5202/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096756609 CMS
Novo Nordisk Inc $19.6402/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097000657 CMS
ABBVIE INC. $17.3001/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105985261 CMS
Novo Nordisk Inc $20.3601/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097683382 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,823.22 39
PY2020 $410.97 28
PY2021 $698.79 47
PY2022 $543.04 31
PY2023 $6,389.49 35
PY2024 $1,915.52 44
PY2025 $1,251.65 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,783,192.12 359
PY2024 Recipient $66,231.01 15
PY2024 Principal investigator $2,510,578.54 317
PY2023 Recipient $6,417.61 4
PY2023 Principal investigator $2,159,960.11 267
PY2022 Principal investigator $2,441,546.83 286
PY2021 Principal investigator $1,166,336.49 169
PY2020 Principal investigator $1,326,147.90 192
PY2019 Principal investigator $636,986.48 193

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

332 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $500.00 12/31/2024 Non-covered Recipient Entity
PMG RESEARCH INC DBA PMG RESEARCH OF MCFARLAND CLINIC
M23-714 Ubrelvy Menstrual Migraine No dispute reported 06/30/2026 1100765841
Principal investigator 1 ModernaTX, Inc. $92,008.87 12/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191518
Principal investigator 1 ModernaTX, Inc. $235,037.35 12/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191512
Principal investigator 1 BioNTech SE $5,026.00 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667431
Principal investigator 1 H. Lundbeck A S $451.00 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145888126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $294.03 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,029.75 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,449.25 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,269.50 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449866
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,355.00 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $293.93 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,774.25 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449934
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,178.75 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449936
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,083.00 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $912.00 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,292.65 12/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082450090
Principal investigator 1 H. Lundbeck A S $28.75 12/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145888076
Principal investigator 1 H. Lundbeck A S $194.50 12/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145888080
Principal investigator 1 ModernaTX, Inc. $68.30 12/11/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191502
Principal investigator 1 BioNTech SE $3,285.00 12/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,139.42 12/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082448084
Principal investigator 1 ABBVIE INC. $578.81 12/09/2024 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1100760519
Principal investigator 1 ABBVIE INC. $578.81 12/09/2024 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1100760521
Principal investigator 1 ModernaTX, Inc. $199.56 12/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191500
Principal investigator 1 BioNTech SE $240.00 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667409
Principal investigator 1 BioNTech SE $600.00 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667413
Principal investigator 1 BioNTech SE $198.00 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667421
Principal investigator 1 BioNTech SE $300.00 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667423
Principal investigator 1 BioNTech SE $300.00 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667425
Principal investigator 1 BioNTech SE $1,800.00 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667457
Principal investigator 1 BioNTech SE $4,929.00 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,142.50 12/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082446730
Principal investigator 1 ModernaTX, Inc. $81.96 11/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191490
Principal investigator 1 ModernaTX, Inc. $6,582.96 11/27/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191486
Principal investigator 1 BioNTech SE $5,827.00 11/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,009.74 11/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $98.01 11/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,106.00 11/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,233.25 11/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,226.44 11/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445914
Principal investigator 1 BioNTech SE $1,000.00 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667435
Principal investigator 1 BioNTech SE $15,485.00 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667455
Principal investigator 1 ModernaTX, Inc. $68.30 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191488
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,701.00 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,297.69 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,050.00 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,626.75 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $399.00 11/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445156
Principal investigator 1 BioNTech SE $17,140.00 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667437
Principal investigator 1 H. Lundbeck A S $22,289.00 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145887570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,197.25 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $855.00 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $385.51 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,811.56 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,155.19 11/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444328
Principal investigator 1 BioNTech SE $6,000.00 11/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667419
Principal investigator 1 BioNTech SE $90.42 11/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667447
Principal investigator 1 BioNTech SE $76.72 11/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667453
Principal investigator 1 BioNTech SE $75.35 11/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667463
Principal investigator 1 BioNTech SE $5,877.00 11/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99,330.21 11/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082443652
Principal investigator 1 BioNTech SE $14,761.00 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,500.00 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082442096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $688.50 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082442098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,025.00 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082442100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082442102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082442104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082442106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,041.00 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082442108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,422.00 10/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082442110
Principal investigator 1 BioNTech SE $14,304.00 10/22/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667411
Principal investigator 1 ModernaTX, Inc. $204.90 10/22/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191472
Principal investigator 1 H. Lundbeck A S $13.25 10/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145887444
Principal investigator 1 H. Lundbeck A S $28.75 10/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145887448
Principal investigator 1 BioNTech SE $11,712.00 10/15/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667459
Principal investigator 1 ModernaTX, Inc. $399.12 10/14/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147191470
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 10/11/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529657
Principal investigator 1 BioNTech SE $97.27 10/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667415
Principal investigator 1 BioNTech SE $97.27 10/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667417
Principal investigator 1 BioNTech SE $474.42 10/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667427
Principal investigator 1 BioNTech SE $15,690.00 10/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667443
Principal investigator 1 BioNTech SE $528.00 10/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667451
Principal investigator 1 BioNTech SE $11,851.00 10/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667439
Principal investigator 1 BioNTech SE $14,581.00 10/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667441
Principal investigator 1 GlaxoSmithKline, LLC. $392.00 10/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529659
Principal investigator 1 GlaxoSmithKline, LLC. $349.00 10/02/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529661
Principal investigator 1 GlaxoSmithKline, LLC. $16,073.05 09/25/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529663
Principal investigator 1 BioNTech SE $817.89 09/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667369
Principal investigator 1 BioNTech SE $16,203.00 09/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667371
Principal investigator 1 BioNTech SE $75.35 09/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667383
Principal investigator 1 BioNTech SE $76.72 09/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667385
Principal investigator 1 BioNTech SE $205.50 09/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667387
Recipient Eli Lilly and Company $63,117.00 09/24/2024 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137348063
Recipient Eli Lilly and Company $1,508.00 09/24/2024 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1137348161
Principal investigator 1 H. Lundbeck A S $80.00 09/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145887352
Principal investigator 1 H. Lundbeck A S $313.00 09/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145887362
Principal investigator 1 H. Lundbeck A S $700.00 09/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145887374
Principal investigator 1 H. Lundbeck A S $73.00 09/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145887384
Principal investigator 1 BioNTech SE $144.00 09/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667381
Principal investigator 1 BioNTech SE $13,611.00 09/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667403
Principal investigator 1 GlaxoSmithKline, LLC. $7,500.00 09/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127527046
Principal investigator 1 BioNTech SE $11,019.00 09/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667391
Principal investigator 1 BioNTech SE $7,083.00 09/03/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667367
Principal investigator 1 BioNTech SE $13,611.00 08/27/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667405
Principal investigator 1 BioNTech SE $80.83 08/27/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667407
Principal investigator 1 GlaxoSmithKline, LLC. $9,427.80 08/27/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529651
Principal investigator 1 BioNTech SE $693.00 08/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667393
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127527054
Recipient Regeneron Pharmaceuticals, Inc. $13.40 08/19/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396990
Recipient Regeneron Pharmaceuticals, Inc. $28.77 08/19/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396992
Recipient Regeneron Pharmaceuticals, Inc. $31.03 08/19/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396994
Principal investigator 1 BioNTech SE $9,023.00 08/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667365
Principal investigator 1 GlaxoSmithKline, LLC. $39.00 08/09/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529599
Principal investigator 1 BioNTech SE $144.00 08/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667379
Principal investigator 1 BioNTech SE $5,364.00 08/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667395
Principal investigator 1 GlaxoSmithKline, LLC. $98.00 08/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529605
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 08/02/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127527050
Principal investigator 1 BioNTech SE $7,124.00 08/01/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667361
Principal investigator 1 BioNTech SE $600.00 07/30/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667397
Principal investigator 1 Eli Lilly and Company $118,766.00 07/30/2024 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137365491
Recipient Regeneron Pharmaceuticals, Inc. $15.10 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396976
Recipient Regeneron Pharmaceuticals, Inc. $15.10 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396978
Recipient Regeneron Pharmaceuticals, Inc. $44.50 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396980
Recipient Regeneron Pharmaceuticals, Inc. $60.40 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396982
Recipient Regeneron Pharmaceuticals, Inc. $70.01 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396984
Recipient Regeneron Pharmaceuticals, Inc. $233.63 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396986
Recipient Regeneron Pharmaceuticals, Inc. $305.89 07/26/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396988
Recipient Regeneron Pharmaceuticals, Inc. $32.57 07/25/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396972
Recipient Regeneron Pharmaceuticals, Inc. $128.98 07/25/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396974
Principal investigator 1 GlaxoSmithKline, LLC. $2,828.15 07/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529655
Principal investigator 1 BioNTech SE $11,435.00 07/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667401
Principal investigator 1 GlaxoSmithKline, LLC. $794.00 07/22/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529595
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 07/17/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529603
Principal investigator 1 BioNTech SE $13,791.00 07/16/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667389
Recipient Regeneron Pharmaceuticals, Inc. $626.63 07/12/2024 Covered Recipient Physician A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082396970
Principal investigator 1 BioNTech SE $24,117.00 07/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667363
Principal investigator 1 BioNTech SE $66.00 07/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667373
Principal investigator 1 BioNTech SE $48.00 07/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667375
Principal investigator 1 BioNTech SE $192.00 07/10/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667377
Principal investigator 1 PFIZER INC. $86,310.00 07/04/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131044809
Principal investigator 1 BioNTech SE $9,675.00 07/02/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667399
Principal investigator 1 BioNTech SE $19,016.00 06/25/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667323
Principal investigator 1 Eli Lilly and Company $103,327.00 06/25/2024 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1137364895
Principal investigator 1 GlaxoSmithKline, LLC. $1,875.60 06/25/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529607
Principal investigator 1 Novo Nordisk AS $16,432.13 06/21/2024 Non-covered Recipient Entity
ACCELLACARE CLINICAL RESEARCH
NN9838-4608 No dispute reported 06/30/2026 1097185528
Principal investigator 1 GlaxoSmithKline, LLC. $1,088.00 06/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127527048
Principal investigator 1 BioNTech SE $31,581.00 06/18/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667309
Principal investigator 1 BioNTech SE $34,076.00 06/11/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667317
Principal investigator 1 ABBVIE INC. $15,000.00 06/06/2024 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1100722054
Principal investigator 1 BioNTech SE $7,048.00 06/06/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667311
Principal investigator 1 BioNTech SE $600.00 06/06/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667343
Principal investigator 1 PFIZER INC. $23,316.00 06/06/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131066398
Principal investigator 1 BioNTech SE $44,654.00 05/28/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667315
Principal investigator 1 BioNTech SE $96.00 05/28/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667339
Principal investigator 1 BioNTech SE $144.00 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667305
Principal investigator 1 BioNTech SE $556.22 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667313
Principal investigator 1 BioNTech SE $600.00 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667333
Principal investigator 1 BioNTech SE $768.57 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667347
Principal investigator 1 BioNTech SE $264.00 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667349
Principal investigator 1 BioNTech SE $48.00 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667353
Principal investigator 1 BioNTech SE $100.00 05/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667357
Principal investigator 1 GlaxoSmithKline, LLC. $5,092.95 05/22/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529665
Principal investigator 1 BioNTech SE $26,164.00 05/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667337
Principal investigator 1 BioNTech SE $43,143.00 05/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667351
Principal investigator 1 BioNTech SE $991.00 05/14/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667331
Principal investigator 1 BioNTech SE $54,923.00 05/14/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667355
Principal investigator 1 BioNTech SE $53,010.00 05/14/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667359
Principal investigator 1 Eli Lilly and Company $4,753.54 04/25/2024 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1137366187
Principal investigator 1 BioNTech SE $35,893.00 04/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667319
Principal investigator 1 Eli Lilly and Company $339.39 04/22/2024 Non-covered Recipient Entity
TRIANGLE MEDICAL RESEARCH ASSOCIATES LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1137369036
Principal investigator 1 GlaxoSmithKline, LLC. $6,421.05 04/22/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529601
Principal investigator 1 BioNTech SE $12,900.00 04/16/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667341
Principal investigator 1 PFIZER INC. $4,495.50 04/13/2024 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1131089860
Principal investigator 1 BioNTech SE $300.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667307
Principal investigator 1 BioNTech SE $300.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667325
Principal investigator 1 BioNTech SE $66.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667327
Principal investigator 1 BioNTech SE $1,500.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667329
Principal investigator 1 BioNTech SE $600.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667335
Principal investigator 1 BioNTech SE $42,317.00 04/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667345
Principal investigator 1 PFIZER INC. $73,077.91 04/12/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131089854
Principal investigator 1 BioNTech SE $25,332.00 04/04/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667321
Principal investigator 1 PFIZER INC. $7,500.00 03/30/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131098507
Principal investigator 1 PFIZER INC. $6,496.20 03/27/2024 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1131098501
Principal investigator 1 BioNTech SE $41,232.00 03/26/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667289
Principal investigator 1 GlaxoSmithKline, LLC. $21,812.00 03/25/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529653
Principal investigator 1 PFIZER INC. $1,040.44 03/21/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1131051203
Principal investigator 1 BioNTech SE $12,347.00 03/19/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667283
Principal investigator 1 BioNTech SE $18,208.00 03/12/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667281
Principal investigator 1 BioNTech SE $5,370.00 03/07/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667277
Principal investigator 1 Seqirus USA Inc $1,000.00 03/06/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459558
Principal investigator 1 Seqirus USA Inc $853.00 03/06/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459560
Principal investigator 1 Seqirus USA Inc $2,000.00 03/06/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459562
Principal investigator 1 Seqirus USA Inc $6,000.00 03/06/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459564
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459362
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459364
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459366
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459368
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459374
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459376
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459378
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459380
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459382
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459384
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459386
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459388
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459390
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459392
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459394
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459396
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459410
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459412
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459414
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459416
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459418
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459420
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459424
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459428
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459430
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459432
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459434
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459436
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459438
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459440
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459442
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459444
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459446
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459448
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459450
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459452
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459454
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459456
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459458
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459478
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459480
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459482
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459484
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459486
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459488
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459490
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459492
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459494
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459496
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459498
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459500
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459538
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459540
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459542
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459546
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459548
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459568
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459570
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459572
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459574
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459576
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459578
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459580
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459582
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459584
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459590
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459592
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459594
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459596
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459598
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459600
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459602
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459606
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459608
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459610
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459612
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459614
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459616
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459618
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459630
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459632
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459634
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459636
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459638
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459640
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459642
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459644
Principal investigator 1 Seqirus USA Inc $131.11 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459646
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459648
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459650
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459682
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459686
Principal investigator 1 Seqirus USA Inc $38.36 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459688
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459696
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459698
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459700
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459716
Principal investigator 1 Seqirus USA Inc $213.58 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459732
Principal investigator 1 Seqirus USA Inc $23.98 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459742
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459748
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459750
Principal investigator 1 Seqirus USA Inc $95.49 03/04/2024 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 1123459752
Principal investigator 1 Bavarian Nordic A/S $2,597.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663878
Principal investigator 1 Bavarian Nordic A/S $1,500.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663882
Principal investigator 1 Bavarian Nordic A/S $2,064.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663894
Principal investigator 1 BioNTech SE $693.00 02/29/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667291
Principal investigator 1 PFIZER INC. $13,284.00 02/29/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1131098395
Principal investigator 1 BioNTech SE $693.00 02/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667287
Principal investigator 1 GlaxoSmithKline, LLC. $8,247.90 02/21/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127529597
Principal investigator 1 PFIZER INC. $500.00 02/21/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1131098402
Principal investigator 1 PFIZER INC. $1,920.00 02/14/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1131098543
Principal investigator 1 Bavarian Nordic A/S $202.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663884
Principal investigator 1 Bavarian Nordic A/S $40.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663890
Principal investigator 1 BioNTech SE $48.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667293
Principal investigator 1 BioNTech SE $900.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667295
Principal investigator 1 BioNTech SE $300.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667297
Principal investigator 1 BioNTech SE $96.00 02/13/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667303
Principal investigator 1 BioNTech SE $1,386.00 01/31/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667285
Principal investigator 1 Eli Lilly and Company $2,480.40 01/31/2024 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1137366665
Principal investigator 1 PFIZER INC. $24,344.25 01/27/2024 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1131108237
Principal investigator 1 GlaxoSmithKline, LLC. $16,148.10 01/24/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1127527052
Principal investigator 1 Novartis Pharmaceuticals Corporation $500.00 01/24/2024 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH PMG RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1089694905
Principal investigator 1 PFIZER INC. $5,356.70 01/24/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131106617
Principal investigator 1 Bavarian Nordic A/S $11,262.00 01/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663886
Principal investigator 1 Bavarian Nordic A/S $1,579.00 01/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663888
Principal investigator 1 Bavarian Nordic A/S $15,000.00 01/23/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663896
Principal investigator 1 PFIZER INC. $2,080.88 01/18/2024 Non-covered Recipient Entity
ACELLACARE US INC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1131048659
Principal investigator 1 PFIZER INC. $157,947.30 01/17/2024 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131108961
Principal investigator 1 BioNTech SE $2,118.00 01/16/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667301
Principal investigator 1 Novartis Pharmaceuticals Corporation $223.63 01/15/2024 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1089688735
Principal investigator 1 BioNTech SE $1,386.00 01/09/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667279
Principal investigator 1 Bavarian Nordic A/S $371.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663876
Principal investigator 1 Bavarian Nordic A/S $1,057.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663880
Principal investigator 1 Bavarian Nordic A/S $516.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663892
Principal investigator 1 Bavarian Nordic A/S $371.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663898
Principal investigator 1 BioNTech SE $3,601.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667275
Principal investigator 1 BioNTech SE $300.00 01/05/2024 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1150667299
Principal investigator 1 Eli Lilly and Company $253,217.00 01/02/2024 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1137365099